<DOC>
	<DOCNO>NCT02733627</DOCNO>
	<brief_summary>The primary objective trial investigate safety tolerability BI 1467335 healthy male female subject follow oral administration multiple rise dos 28 day . Secondary objective exploration pharmacokinetics ( PK ) target engagement biomarkers BI 1467335 multiple dosing .</brief_summary>
	<brief_title>To Investigate Safety , Tolerability , Pharmacokinetics Pharmacodynamics BI 1467335 Following Multiple Dose Administration Over 28 Days</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male female subject accord investigator 's assessment , base complete medical history include physical examination , vital sign , Blood pressure ( BP ) , Pulse rate ( PR ) , 12lead Electrocardiogram ( ECG ) , clinical laboratory Age 18 50 year ( incl . ) Body mass index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance Good Clinical Practice ( GCP ) local legislation Male subject , female subject meet follow criterion start least 30 day first administration trial medication 30 day trial completion : Surgically sterilise ( include hysterectomy ) Postmenopausal , define least 1 year spontaneous amenorrhea ( questionable case blood sample simultaneous level Follicle Stimulating Hormone ( FSH ) 40 U/L estradiol 30 ng/L confirmatory ) Exclusion criterion : Any find medical examination ( include Blood pressure ( BP ) , Pulse rate ( PR ) Electrocardiogram ( ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection History relevant allergy hypersensitivity ( include allergy trial medication excipients ) Intake drug long halflife ( 24 h ) within 30 day less 10 halflives respective drug prior administration trial medication Within 10 day prior administration trial medication , use drug might reasonably influence result trial might prolong QT/QTc interval Participation another trial investigational drug administer within 60 day prior plan administration trial medication Used nicotinecontaining product ( e.g. , cigarette , cigar , chew tobacco , snuff ) within 6 week screen unable abstain use product study completion Alcohol abuse ( consumption 20 g per day females 30 g per day male ) Drug abuse positive drug screen Blood donation 100 mL within 30 day prior administration trial medication intend donation trial Intention perform excessive physical activity within one week prior administration trial medication trial Inability comply dietary regimen trial site A marked baseline prolongation QT/corrected QT ( QTc ) interval ( QTc interval repeatedly great 450 m male repeatedly great 470 m female ) relevant ECG find screen A history additional risk factor Torsades de Pointes ( heart failure , hypokalemia , family history Long QT Syndrome ) Subject assess unsuitable inclusion investigator , instance , consider able understand comply study requirement , condition would allow safe participation study Detection cataract slit lamp examination GFR accord CKDEPIFormula &lt; 90 mL/min screen Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>